Pharma Told To Maintain Drug Stockpiles Despite Six-Month Brexit Delay
An agreement to delay Brexit has brought no reprieve for the pharmaceutical sector, which must remain at a heightened state of preparedness as a no-deal scenario is still a possibility. Industry says it will seek clarity on the practical implications of this.
You may also be interested in...
A leaked government note has thrown doubt on the ability of the pharma sector to be ready for a no-deal Brexit in October, even though some of the contenders to be the next prime minister say there is nothing to fear from the UK leaving the EU without a deal.
The BioIndustry Association wants to discuss the importance of close post-Brexit regulatory alignment with the new European Parliament and will also press its message on the next leader of the Conservative Party after prime minister Theresa May steps down.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.